Pulaski Law Firm Warns Consumers of Invokana Drug Risks

(Newswire.net — July 9, 2015) Houston, Texas — Many people who have taken the medication Invokana to treat their diabetes have required extensive treatment, with some users experiencing severe injury such as ketoacidosis and kidney failure. Consumer advocacy group Public Citizen argued against the FDA originally approving the drug in 2013, stating that there was not enough safety information available at the time to release it. Since that time, over 450 serious adverse events have occurred in users. In addition, 2 million prescriptions for Invokana have been filled, yet most patients remain unaware of the most serious risks associated with use of SGLT2 inhibitors to treat their type II diabetes.

One of the main dangers associated with taking Invokana is the risk of developing a condition called diabetic ketoacidosis. This condition occurs when the body is unable to burn sugar as an energy source, so it burns fat and muscle instead. When the body burns too much fat in rapid succession, ketones, which are a chemical substance, end up in the blood. This turns the blood acidic and is potentially deadly if not treated. Unfortunately, countless users of Invokana and other SGLT2 inhibitors have been unaware of these risks.  In light of the dangers posed by these SGLT2 inhibitors, the FDA issued a warning in May 2015 stating that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, and that this serious condition often requires hospitalization for these patients.

Symptoms of diabetic ketoacidosis include fatigue, weakness, and dehydration to in the early stages. This condition can quickly advance, however, into vomiting, dizziness, and unconsciousness. The latter symptoms can become fatal if not treated right away. Other side effects that are associated with Invokana, but not necessarily related to diabetic ketoacidosis, include UTIs, yeast infections, rashes, sun intolerance, low blood pressure, kidney problems, and allergic reactions.

The Pulaski Law Firm, one of the nation’s leading pharmaceutical litigation firms, is currently accepting cases from people with type II diabetes who used an SGLT2 medication, such as Invokana (canagliflozin), Farxiga, or Glyxambi, to help lower blood sugar levels and suffered a serious injury like ketoacidosis or kidney failure. The Pulaski Law Firm is dedicated to helping those injured by dangerous pharmaceutical drugs and medical devices. Our firm has helped thousands of patients nationwide file successful lawsuits against pharmaceutical companies, resulting in significant settlements for their lost wages, medical expenses, pain, and suffering.

Anyone who has taken Invokana, Farxiga, or Glyxambi, and suffered a serious side effect or death, may be entitled to compensation. Those injured should contact the Invokana lawyers at the Pulaski Law Firm at 1-800-Bad Drug (800-223-3784) for a free case evaluation. Patients and their families can also visit www.1800BadDrug.com for more information regarding Invokana claims.